Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
- PMID: 31614473
- PMCID: PMC6832516
- DOI: 10.3390/toxins11100586
Promise and the Pharmacological Mechanism of Botulinum Toxin A in Chronic Prostatitis Syndrome
Abstract
Chronic prostatitis/chronic pelvic pain syndrome (CP/ CPPS) has a negative impact on the quality of life, and its etiology still remains unknown. Although many treatment protocols have been evaluated in CP/CPPS, the outcomes have usually been disappointing. Botulinum neurotoxin A (BoNT-A), produced from Clostridium botulinum, has been widely used to lower urinary tract dysfunctions such as detrusor sphincter dyssynergia, refractory overactive bladder, interstitial cystitis/bladder pain syndromes, benign prostatic hyperplasia, and CP/ CPPS in urology. Here, we review the published evidence from animal models to clinical studies for inferring the mechanism of action underlying the therapeutic efficacy of BoNT in CP/CPPS. Animal studies demonstrated that BoNT-A, a potent inhibitor of neuroexocytosis, impacts the release of sensory neurotransmitters and inflammatory mediators. This pharmacological action of BoNT-A showed promise of relieving the pain of CP/CPPS in placebo-controlled and open-label BoNT-A and has the potential to serve as an adjunct treatment for achieving better treatment outcomes in CP/CPPS patients.
Keywords: Botulinum toxin; chronic prostatitis.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature.Toxins (Basel). 2016 Mar 23;8(4):88. doi: 10.3390/toxins8040088. Toxins (Basel). 2016. PMID: 27023601 Free PMC article. Review.
-
Transurethral intraprostatic injection of botulinum neurotoxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double-blind and randomized placebo-controlled study.BJU Int. 2015 Oct;116(4):641-9. doi: 10.1111/bju.12951. Epub 2015 May 25. BJU Int. 2015. PMID: 25307409 Clinical Trial.
-
Can Botulinum Toxin A Play A Role In Treatment Of Chronic Pelvic Pain Syndrome In Female Patients?-Clinical and Animal Evidence.Toxins (Basel). 2020 Feb 10;12(2):110. doi: 10.3390/toxins12020110. Toxins (Basel). 2020. PMID: 32050685 Free PMC article. Review.
-
Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.Expert Opin Biol Ther. 2015 Jan;15(1):95-102. doi: 10.1517/14712598.2015.974543. Epub 2014 Oct 27. Expert Opin Biol Ther. 2015. PMID: 25347039 Review.
-
Multidisciplinary approach to prostatitis.Arch Ital Urol Androl. 2019 Jan 18;90(4):227-248. doi: 10.4081/aiua.2018.4.227. Arch Ital Urol Androl. 2019. PMID: 30655633
Cited by
-
Systemic and intrathecal baclofen produce bladder antinociception in rats.BMC Urol. 2021 Oct 4;21(1):139. doi: 10.1186/s12894-021-00899-0. BMC Urol. 2021. PMID: 34607587 Free PMC article.
-
Botulinum Toxin Paves the Way for the Treatment of Functional Lower Urinary Tract Dysfunction.Toxins (Basel). 2020 Jun 14;12(6):394. doi: 10.3390/toxins12060394. Toxins (Basel). 2020. PMID: 32545870 Free PMC article.
-
Mechanism of Action of Botulinum Toxin A in Treatment of Functional Urological Disorders.Toxins (Basel). 2020 Feb 18;12(2):129. doi: 10.3390/toxins12020129. Toxins (Basel). 2020. PMID: 32085522 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous